Monitor upcoming MICVO data readouts in Fall 2026 (monotherapy Phase 1) and Q4 2026 (combination Phase 1/2), these are the primary catalysts. The leadership transition is neutral and removes interim uncertainty.
Drug in focus
PYXS drug pipeline →PYX-201
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 1 / Phase 1/2
- Time to market
- At least 2-3 years, assuming Phase 3 trial (planned mid-2027) succeeds and leads to an NDA filing. No regulatory filing has occurred yet.
- Next catalyst
- None dated
What to watchThe next near-term catalyst is the EORTC-NCI-AACR late-breaking oral presentation (Nov 18-20, 2026), though the top-line data has already been disclosed. The true binary events are: Q4 2026 updated combo data, Q1 2027 End-of-Phase 2 meeting with FDA, and H1 2027 overall survival data from the monotherapy study, any of which could drive major moves. The $3.50 common warrant exercise trigger (requiring both shareholder approval and OS data) creates an additional overhang that could cap upside until clarity emerges.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 8 $3.89entry
- T+1 · 2mo ago −13.11%α −12.65% · $3.38
- T+5 · 2mo ago −14.40%α −13.28% · $3.33
- T+20 · 6w ago −48.07%α −49.79% · $2.02
- T+49 · todayOpen
- T+60 · in 15d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pyxis Oncology appointed interim CEO Thomas Civik as permanent CEO and Chairman, replacing John Flavin who becomes Lead Independent Director. Board member Dr. Santhosh Palani resigned. The filing is a routine leadership transition with no material financial data, the company remains a clinical-stage biotech awaiting key MICVO data readouts in Fall 2026 and Q4 2026.
Key Facts
- Thomas Civik appointed permanent CEO and Chairman, effective September 4, 2026, after serving as interim CEO since February 2, 2026.
- John Flavin transitions from Chairman to Lead Independent Director and Chair of Compensation Committee.
- Dr. Santhosh Palani resigned from the Board effective September 4, 2026, citing increased time commitments; Board reduced from 8 to 7 members.
- Civik receives $710,000 annual base salary, 60% target bonus, $100,000 sign-on bonus, and a nonqualified stock option for 2,503,050 shares.
- Company expects to report updated MICVO Phase 1 monotherapy data in Fall 2026 and Phase 1/2 combination data with pembrolizumab in Q4 2026.
Financial Impact
No financial results reported. CEO compensation: $710k salary, 60% target bonus, $100k sign-on bonus, option grant for 2,503,050 shares.
Risk Factors
- Clinical-stage biotech with no approved products, MICVO data readouts are binary events.
- CEO/Chairman role combination reduces independent board oversight, though Lead Independent Director position was established.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-384386 |
| Document: pyxs-ex99_1.htm | 0001193125-26-384386 |
| Document: 0001193125-26-384386-index-headers.html | 0001193125-26-384386 |
| Document: 0001193125-26-384386-index.html | 0001193125-26-384386 |
| Document: 0001193125-26-384386.txt | 0001193125-26-384386 |
Track record
25 reports on PYXS
6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.94% at T+60 after the Apr 17, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.43 Now $1.41 −1.32% settles Dec 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.43 Now $1.41 −1.40% settles Dec 16
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.55 Now $1.41 −9.14% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $1.61 Now $1.41 −12.42% settles Dec 4
- Nov 3, 202613d ago SC 13G/A Bearish 5/10 Entry $1.64 Now $1.41 +14.02% settles Dec 2
- Oct 27, 202620d ago Press Release Neutral 4/10 Entry $1.84 Now $1.41 −23.37% settles Nov 24
- Oct 21, 202626d ago DEF 14A Bearish 6/10 Entry $1.71 Now $1.41 +17.54% settles Nov 19
- Oct 9, 20265w ago SC 13G/A Neutral 4/10 Entry $2.03 to $1.66 Now $1.41 −30.54% ▼ −18.23% −12.67% vs SPY
- Oct 2, 20266w ago SC 13G/A Neutral 4/10 Entry $2.14 to $1.81 Now $1.41 −34.11% ▼ −15.42% −13.61% vs SPY
- Oct 2, 20266w ago Press Release Bearish 7/10 Entry $2.14 to $1.81 Now $1.41 +34.11% ▲ +15.42% +13.61% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers